[ad_1]
FILE PHOTO: The logo of Gilead Sciences Inc. appears on the photo at a press conference in New Delhi on September 15, 2014. REUTERS / Anindito Mukherjee
(Reuters) – Gilead Sciences Inc. (GILD.O) will increase its stake in Galapagos NV (GLPG.AS) and get rights out of Europe on the treatments of the Belgian-Dutch biotech company under development under a $ 5.1 billion deal, reported Sunday the Wall Street Journal.
The US drug maker Gilead will invest $ 1.1 billion, or 140.59 euros per share, to increase its stake in Galapagos from 12.3% to 22% and make a separate payment of $ 3.95 billion to Galapagos, announced WSJ
The terms of the agreement, including the research collaboration, are to be announced on Sunday, the Journal added.
Report by Ismail Shakil in Bengaluru, edited by Rosalba O & # 39; Brien
Source link
